| Utc Health And Rehab - Pearland | |
|
2620 Cullen Blvd, Suite 202, Pearland, TX 77581-8961 | |
| (281) 412-0900 | |
| (281) 412-4020 |
| Full Name | Utc Health And Rehab - Pearland |
|---|---|
| Type | Facility |
| Speciality | Family Medicine |
| Location | 2620 Cullen Blvd, Pearland, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003351768 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111NR0400X | Chiropractor - Rehabilitation | (* (Not Available)) | Secondary |
| 207Q00000X | Family Medicine | AP1202492 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Utc Health And Rehab - Pearland 8900 Shoal Creek Blvd, Suite 200, Austin, TX 78757-6810 Ph: (512) 323-6900 | Utc Health And Rehab - Pearland 2620 Cullen Blvd, Suite 202, Pearland, TX 77581-8961 Ph: (281) 412-0900 |
News Archive
Instead of threading catheters from the femoral artery in the groin, cardiologists can safely use the radial artery in the arm to gain access to coronary arteries for angioplasty, stent placement, and other procedures
COVID-19 spreads faster and more widely throughout U.S. households than previously reported, according to new preliminary research from a multicenter study led by Vanderbilt University Medical Center researchers and published in MMWR, a weekly report from the Centers for Disease Control and Prevention.
Gilead Sciences, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for marketing approval for the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil (as fumarate)) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine (as hydrochloride)) for the treatment of HIV-1 infection in adults.
Studies screening the genome of hundreds of thousands of individuals (known as Genome-wide association studies or GWAS) have linked more than 100 regions in the genome to the risk of developing cardiovascular disease.
Current research suggests that tumor-secreted exosomes inhibit the immune response, enhancing tumor metastasis. The related report by Liu et al, "Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells," appears in the May 2010 issue of The American Journal of Pathology.
› Verified 3 days ago